Incidence of cancer in patients with multiple sclerosis (MS) who were treated with fingolimod: A systematic review and meta-analysis

Askari, Mozhde; Mirmosayyeb, Omid; Ghaffary, Elham Moases; Ghoshouni, Hamed; Shaygannejad, Vahid; Ghajarzadeh, Mahsa

doi:10.1016/j.msard.2022.103680

Cited by 3 publications

(5 citation statements)

References 46 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Furthermore, based on a systematic review and meta‐analysis study that reviewed the data of 64,135 patients, 6 the risk of cancer in pwMS using Fingolimod 0.5 mg is evaluated to be about 2.01% (95% CI: 1.00%–2.04%). This number boosted to 3.01% (95% CI: 2.02%–5.01%) in the dose of 1.25 mg, showing that increasing the drug dose can increase the probability of cancer in pwMS.…”

Section: Discussionmentioning

confidence: 99%

“…It should be noted that according to various case reports of Fingolimod‐induced cancer, the specific point of this case is the type of cancer identified, that is, bladder lymphoma, which has not been reported by any study so far. This patient has long‐term taken of fingolimod compared to a previous study, 6 which can increase the risk of developing cancer due to the long‐term use of the medication. Furthermore, the absence of a family history of cancer and other typical carcinogenic and mutagenic factors, such as smoking or occupational exposure to chemicals, may reduce the possibility that bladder lymphoma may be caused by factors other than long‐term Fingolimod use in this case.…”

Section: Discussionmentioning

confidence: 99%

“…Blocking immunosurveillance of B-cell lymphoma and myeloma via CD4 T cell is a suggestive pathophysiological pathway due to the increased risk of cancer in long-term use of fingolimod in patients. 8 Furthermore, based on a systematic review and metaanalysis study that reviewed the data of 64,135 patients, 6 the risk of cancer in pwMS using Fingolimod 0.5 mg is evaluated to be about 2.01% (95% CI: 1.00%-2.04%). This number boosted to 3.01% (95% CI: 2.02%-5.01%) in the dose of 1.25 mg, showing that increasing the drug dose can increase the probability of cancer in pwMS.…”

Section: Outcome and Follow-upmentioning

confidence: 99%

“…Even so, few studies have investigated cancer in patients receiving Fingolimod 6 , 7 ; this may be due to the rarity of this adverse effect in the patient population. As of yet, there has been no reported case of bladder lymphoma in pwMS taking long‐term Fingolimod.…”

Section: Introductionmentioning

confidence: 99%

See 3 more Smart Citations

Fingolimod‐induced bladder lymphoma in a patient with multiple sclerosis

Vaheb

Ghaffary

Shaygannejad

et al. 2023

Clinical Case Reports

Self Cite

View full text Add to dashboard Cite

Key Clinical Message Malignancies were reported in some studies following taking Fingolimod. We reported a case of bladder lymphoma after taking Fingolimod. Physicians should consider the carcinogenic effects of Fingolimod in long‐term use and replace it with safer medicines. Abstract Fingolimod is a medication with a potential cure to control multiple sclerosis (MS) relapses. Here we describe a 32‐year‐old woman with relapsing–remitting multiple sclerosis who developed bladder lymphoma induced by long‐term use of Fingolimod. Physicians should consider the carcinogenic effects of Fingolimod in long‐term use and replace it with safer medicines.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Section: Outcome and Follow-upmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Fingolimod‐induced bladder lymphoma in a patient with multiple sclerosis

Vaheb

Ghaffary

Shaygannejad

et al. 2023

Clinical Case Reports

Self Cite

View full text Add to dashboard Cite

show abstract

“…[ 9 ] Fingolimod inhibits lymphocyte egress from the lymph node, leading to inhibition of lymphocyte infiltration into the CNS. [ 18 19 ]…”

Section: Discussionmentioning

confidence: 99%

The Efficacy of Fingolimod and Interferons in Controlling Disability and Relapse Rate in Patients with Multiple Sclerosis: A Systematic Review and Meta-Analysis

Shaygannejad,

Mirmosayyeb,

Bagherieh

et al. 2023

International Journal of Preventive Medicine

Self Cite

View full text Add to dashboard Cite

Background: Fingolimod and interferons are used in the relapse form of multiple sclerosis (MS). The goal of this systematic review and meta-analysis was to evaluate the efficacy of fingolimod versus interferon in patients with MS. The systematic search was done in PubMed, Scopus, Embase, Web of Science, and Google Scholar. Methods: The references of included studies as well as conference abstracts were searched up to July 2021. The literature search revealed 8211 articles, and after deleting duplicates 5594 remained. For the meta-analysis, four studies were included. The standardized mean difference (SMD) of the Expanded Disability Status Scale (EDSS) after treatment (interferon vs fingolimod) was −0.06 (95% CI: −0.28, 0.17) (I2 = 80.2%, P = 0.002). Results: The SMD of the annual relapse rate (ARR) after treatment (interferon – fingolimod) was −0.08 (95% CI: −0.53, 0.36) (I2 = 95.5%, P < 0.001). The SMD of the ARR after treatment and before treatment in the interferon group was − 1.45, (95% CI: −1.55, −1.36) (I2 = 0, P = 0.3). The SMD of ARR after treatment and before treatment in the fingolimod group was − 1.3, (95% CI: −1.94, −0.65) (I2 = 97.4%, P < 0.001). Conclusions: The results of this systematic review show that efficacy of interferon and fingolimod in controlling relapse rate and disability is similar.

show abstract

Drug-induced tumoral disease: A global pharmacovigilance database analysis

Zelmat,

Despas

2024

Therapies

View full text Add to dashboard Cite

Incidence of cancer in patients with multiple sclerosis (MS) who were treated with fingolimod: A systematic review and meta-analysis

Cited by 3 publications

References 46 publications

Fingolimod‐induced bladder lymphoma in a patient with multiple sclerosis

Fingolimod‐induced bladder lymphoma in a patient with multiple sclerosis

The Efficacy of Fingolimod and Interferons in Controlling Disability and Relapse Rate in Patients with Multiple Sclerosis: A Systematic Review and Meta-Analysis

Drug-induced tumoral disease: A global pharmacovigilance database analysis

Contact Info

Product

Resources

About